Neurocrine Biosciences [NBIX]

Neurocrine Biosciences Inc is a pharmaceutical firm dedicated to the creation advancement and commercialization of medicines addressing a spectrum of neurological endocrine and psychiatric conditions Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia Parkinsons disease endometriosis and uterine fibroids alongside numerous experimental compounds in various clinical stages The companys primary commercial asset is INGREZZA a VMAT2 inhibitor indicated for the management of tardive dyskinesia Other available treatments include ONGENTYS which serves as an auxiliary therapy for individuals with Parkinsons disease who are also receiving levodopaDOPA decarboxylase inhibitors ORILISSA prescribed for the alleviation of moderate to severe pain linked with endometriosis in women and ORIAHNN an oral nonsurgical option for premenopausal women experiencing significant menstrual bleeding associated with uterine fibroids Furthermore Neurocrine is actively progressing a number of drug candidates through clinical development These include NBI921352 for treating pediatric patients and adult focal epilepsy NBI827104 designed to address rare pediatric epilepsy and essential tremor NBI1065845 for major depressive disorder NBI1065846 specifically for anhedonia within major depressive disorder and NBI118568 for the treatment of schizophrenia The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited Takeda Pharmaceutical Company Limited Idorsia Pharmaceuticals Ltd Xenon Pharmaceuticals Inc Voyager Therapeutics Inc BIAL Portela Ca SA Mitsubishi Tanabe Pharma Corporation and AbbVie Inc Neurocrine Biosciences Inc was founded in 1992 and operates from its headquarters in San Diego California